The FDA issued a warning letter to Peak Performance Peptides, an online seller, for marketing unapproved injectable peptide drugs including retatrutide, semaglutide, PT-141, tesamorelin, and SS-31 via its website. The agency stated these products are unapproved new drugs under the FD&C Act and warned of possible seizure or injunction if violations are not corrected. The letter highlights ongoing FDA scrutiny of grey-market peptide sellers.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.